The Effect of ZD 1839 (Iressa(R)) in the Treatment of Refractory Non Small Cell Lung Cancer

Kim, Yong Tai; Kim, Chul; Sohn, Joo Hyuk; Park, So Young; Park, Soo Young; Yu, Nae Choon; Kim, Young Sam; Kim, Se Kyu; Chang, Joon; Kim, Kil Dong; Chung, Kyung Young; Kim, Joo Hang

doi:2003.35.6.502

Cancer Research and Treatment > Volume 35(6); 2003 > Article

Original Article

Cancer Research and Treatment 2003;35(6): 502-506. doi: https://doi.org/10.4143/crt.2003.35.6.502

The Effect of ZD 1839 (Iressa(R)) in the Treatment of Refractory Non Small Cell Lung Cancer

Yong Tai Kim, Chul Kim, Joo Hyuk Sohn, So Young Park, Soo Young Park, Nae Choon Yu, Young Sam Kim, Se Kyu Kim, Joon Chang, Kil Dong Kim, Kyung Young Chung, Joo Hang Kim

¹Yonsei Cancer Center, Yonsei University College of Medicine,Seoul, Korea. kjhang@yumc.yonsei.ac.kr
²Division of Hemato-Oncology, Department of InternalMedicine, Yonsei University College of Medicine, Seoul,Korea.
³Division of Pulmonology, Department of Internal Medicine,Yonsei University College of Medicine, Seoul, Korea.
⁴Department of Thoracic and Cardiovascular Surgery, YonseiUniversity College of Medicine, Seoul, Korea.

Published online: December 31, 2003.

ABSTRACT

PURPOSE:
The aim of this study was to evaluate the efficacy and the safety of ZD 1839 (Iressa(R)) as a 3rd or 4th line chemotherapy regimen in NSCLC patients who are refractory to a previous chemotherapy regimen.
MATERIALS AND METHODS:
Twenty-five patients who were refractory to previous chemotherapy were selected for this study. The eligible patients had an ECOG performance status of 0 to 2, and an appropriate end organ function. ZD 1839 (Iressa(R))250 mg/d was orally administered until the patients experienced disease progression or unacceptable toxicity.
RESULTS:
Twenty-five patients were analyzed. The median age of the patients was 57 years. The response rate was 12.0% with partial responses in 3 patients. Fourteen patients (56%) remained in the stable disease state and 8 patients progressed. The median overall survival was 9.0 months (95% CI 6.7~11.2). The median progression free survival was 3 months (95% CI 2.2~3.8). Hematological toxicities of grade 3 or 4 neutropenia, anemia and thrombocytopenia were absent. Non-hematological toxicities were grade 2 or 3 skin rashes in 10 (40.0%) patients and 1 (4.0%) patient and grade 3 nausea in 3 (12.0%) patients. No patient failed to continue chemotherapy due to any drug-related adverse events.
CONCLUSION:
The results suggest that ZD 1839 (Iressa(R)) monotherapy is effective and tolerable as a 3rd or 4th line salvage treatment for NSCLC patients refractory to previous chemotherapy regimens.

Key words: ZD1839 (Iressa(R));Non-small cell lung cancer